Table 3 |
||||||
|
Observational study characteristics |
||||||
|
Study |
Number of patients |
Mean age (years) |
Outcome measurea |
CYC treatment |
Corticosteroid |
Length of follow-up (months) |
|
|
||||||
|
Airò and colleagues [15] |
13 |
48 |
FVC, 74 |
Intravenous, 750 mg/m2 every 3 weeks |
Methylprednisolone 125 mg every 3 weeks |
18 |
|
DLCO, 41 |
||||||
|
Beretta and colleagues [14] |
33 |
49.7 ± 10.4 |
DLCO, 48.8 ± 13.5 |
Oral, 2 mg/kg/day |
Prednisone 25 mg/day in the first 3 months, 5 mg for 9 months |
12 |
|
Davas and colleagues, pulse CYC [12] |
8 |
NA |
FVC, 86.1 |
Intravenous, 750 mg/m2 monthly |
Prednisone 10 mg/day |
12 |
|
DLCO, 60 |
||||||
|
Davas and colleagues, oral CYC [12] |
8 |
NA |
FVC, 73.2 |
Oral, 2 to 2.5 mg/kg/day |
Prednisone 10 mg/day |
12 |
|
DLCO, 59.9 |
||||||
|
Pakas and colleagues, low-dose prednisone cohort [16] |
12 |
48.6 ± 12.3 |
FVC, 54.8 |
Intravenous, 900 mg/kg (mean value) |
Prednisone low dose, <10 mg/day |
12 |
|
DLCO, 38.2 |
||||||
|
Pakas and colleagues, high-dose prednisone cohort [16] |
16 |
48.6 ± 12.3 |
FVC, 57.5 |
Intravenous, 900 mg/kg (mean value) |
Prednisone: high dose, 1 mg/kg/day for 4 weeks |
12 |
|
DLCO, 48.3 |
||||||
|
Silver and colleagues [17] |
14 |
46.4 ± 2.4 |
FVC, 51.4 ± 2.5 |
Oral, 1 to 2 mg/kg/day |
Prednisone 7.7 ± 1.2 mg/day (in 10 patients) |
24 |
|
DLCO, 54.5 ± 7.4 |
||||||
|
Valentini and colleagues [18] |
13 |
37.4 |
DLCO, 58.5 |
Intravenous, 500 mg/m2 on day 1, day 8 and day 15, and every 4 weeks |
Low dose corticosteroids (dose not specified) |
12 |
|
|
||||||
|
Data presented as mean ± standard deviation. AZA, azathioprine; CYC, cyclophosphamide; DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity; NA, not available. aPercentage predicted value at baseline. |
||||||
|
Nannini et al. Arthritis Research & Therapy 2008 10:R124 doi:10.1186/ar2534 |
||||||
